Arca
Skip to content

Retinitis pigmentosa (rp)

Drug research and approvals for retinitis pigmentosa (rp): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 16 studies of retinitis pigmentosa (rp) are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, and FDA has 0 approved and 51 open orphan designations naming it.

  • Recruiting worldwide: 16
  • Trials authorized in Canada: 6
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 16 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Oct 16, 2024A two-year double-masked, randomized, sham-controlled study to evaluate the efficacy, safety and tolerability of ultevursen in subjects with retinitis…ULTEVURSENLABORATOIRES THÉAOngoing
Aug 23, 2024A phase 3, multi-center, randomized study to assess the efficacy, safety and tolerability of subretinal ocu400 gene therapy for the treatment of retinitisOCU400OCUGENOngoing
Apr 29, 2022A double-masked, randomized, controlled, multiple-dose study to evaluate the efficacy, safety and tolerability of qr-421a in subjects with retinitis pigmentosa…QR-421APROQR THERAPEUTICS IV BVPending
Dec 2, 2021Phase 3 follow-up study of aav5-hrkp.rpgr for the treatment of x-linked retinitis pigmentosa associated with variants in the rpgr geneAAV5-HRKP.RPGR/ TRIAMCINOLONE ACETONIDEJohnson & JohnsonOngoing
Sep 29, 2021An open-label extension study to evaluate the safety and tolerability of qr-421a in subjects' with retinitis pigmentosa (rp) due to mutations in exon 13 of the…QR-421APROQR THERAPEUTICSClosed
Feb 15, 2019A first-in-human study (fih) to evaluate the safety and tolerability of qr-421a in subjects with retinitis pigmentosa (rp) due to mutations in exon 13 of the…QR-421APROQR THERAPEUTICS IV BVClosed

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 51
Oct 26, 2026small molecule corrector of rhodopsintreatment of retinitis pigmentosaOctant, Inc.Designated
Sep 23, 2026AAV-mediated anti-PROX1 gene therapy…treatment of retinitis pigmentosaCelliaz Ltd.Designated
Mar 26, 2026retinal cells derived from allogeneic human induced…treatment of retinitis pigmentosaAgnos Therapeutics, Inc.Designated
Mar 23, 2026tripentadecanointreatment of retinitis pigmentosaSunRegen Healthcare AGDesignated
Mar 12, 2026allogeneic self-organized three-dimensional retinal…treatment of retinitis pigmentosaSumitomo Pharma America IncDesignated
Feb 14, 2026a cell-based therapeutic composed of purified human rod…treatment of retinitis pigmentosaInGel Therapeutics Inc.Designated
Dec 10, 2025allogeneic human induced pluripotent stem cell-derived…treatment of retinitis pigmentosaBlueRock Therapeutics LPDesignated
May 1, 2025recombinant adeno-associated virus vector expressing…treatment of retinitis pigmentosaBionic Sight, Inc.Designated
Apr 16, 2025N6-(3-aminopropyl)-L-lysine trihydrochloridetreatment of retinitis pigmentosaRen Bioscience LLCDesignated
Mar 3, 2025adeno-associated virus vector with a codon-optimized…treatment of retinitis pigmentosaGenAns Biotechnology Co., LtdDesignated
Oct 28, 2024recombinant human adeno-associated virus serotype 2…treatment of retinitis pigmentosaZhongmou Therapeutics, Inc.Designated
Sep 25, 2024adeno associated virus carrying opn3treatment of retinitis pigmentosaNeoVec Biotherapeutics Inc.Designated
Sep 23, 2024recombinant adeno-associated virus 5 vector expressing a…treatment of autosomal recessive retinitis pigmentosa due to CNGB1 mutationsNational Institutes of Health National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS)Designated
Aug 20, 2024adeno-associated virus (AAV) gene therapy product that…treatment of retinitis pigmentosaSkyline Therapeutics (US) Inc.Designated
Mar 20, 2024Human induced pluripotent stem cells (iPSC)-derived…Treatment of Retinitis PigmentosaiRegene Therapeutics Co., LtdDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.